Literature DB >> 29444417

A study on the regenerative effect of platelet-rich plasma on experimentally induced hepatic damage in albino rats.

Heba Mamdoh Shoeib1,1, Walaa Arafa Keshk1,1, Abdallah Mahmoud Foda1,1, Saad El-Deen Abd Elfatah Abo El Noeman1,1.   

Abstract

Hepatic fibrosis is a worldwide health problem with significant morbidity and mortality. Currently, there is no effective therapy for hepatic fibrosis. The present study was aimed to evaluate the possible regenerative effect of platelet-rich plasma (PRP) against thioacetamide (TAA)-induced hepatic damage. Eighty albino rats were included; 40 were used for PRP preparation and 40 were randomly divided into 4 groups: group I (control group); group II (PRP control); group III (TAA-intoxicated by a dose of 200 mg/kg body mass, intraperitoneally, twice weekly for 7 weeks), and group IV (TAA intoxicated + PRP treated). Macrophage inflammatory protein-1α (MIP-1α) and cyclic adenosine monophosphate (cAMP) were immunoassayed in addition to peroxinitrite level, NADPH-quinone oxidoreductase-1 (NQO1) enzyme activity, and liver function. PRP treatment showed significant improvement in hepatic function, and decreased MIP-1α and peroxinitrite levels. Meanwhile, significant increase in NQO1 enzyme activity and cAMP level were observed. The histopathological results confirmed the laboratory results with improvement of hepatic architecture except for some inflammatory cellular infiltrates. This study shows that PRP has the ability to protect against TAA-induced liver damage, possibly by improving redox status, liver histopathological architecture, and disruption of the inflammatory and fibrotic response induced by TAA.

Entities:  

Keywords:  NADPH quinone oxido-réductase 1; NADPH-quinone oxidoreductase-1; adénosine monophosphate cyclique; cyclic adenosine monophosphate; macrophage inflammatory protein-1α; plasma riche en plaquettes; platelet-rich plasma; protéine inflammatoire-1α des macrophages; thioacetamide; thioacétamide

Mesh:

Year:  2018        PMID: 29444417     DOI: 10.1139/cjpp-2017-0738

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  5 in total

1.  Optimized platelet rich plasma releasate (O-rPRP) repairs galactosemia-induced ovarian follicular loss in rats by activating mTOR signaling and inhibiting apoptosis.

Authors:  Wesam El Bakly; Marwa Medhat; Mohamed Shafei; Reham Tash; Mohamed Elrefai; Yousef Shoukry; Nesreen Nabil Omar
Journal:  Heliyon       Date:  2020-09-21

2.  Platelet-Rich Plasma Prevents In Vitro Transforming Growth Factor-β1-Induced Fibroblast to Myofibroblast Transition: Involvement of Vascular Endothelial Growth Factor (VEGF)-A/VEGF Receptor-1-Mediated Signaling .

Authors:  Flaminia Chellini; Alessia Tani; Larissa Vallone; Daniele Nosi; Paola Pavan; Franco Bambi; Sandra Zecchi Orlandini; Chiara Sassoli
Journal:  Cells       Date:  2018-09-19       Impact factor: 6.600

3.  Platelet-Rich Plasma Modulates Gap Junction Functionality and Connexin 43 and 26 Expression During TGF-β1-Induced Fibroblast to Myofibroblast Transition: Clues for Counteracting Fibrosis.

Authors:  Roberta Squecco; Flaminia Chellini; Eglantina Idrizaj; Alessia Tani; Rachele Garella; Sofia Pancani; Paola Pavan; Franco Bambi; Sandra Zecchi-Orlandini; Chiara Sassoli
Journal:  Cells       Date:  2020-05-12       Impact factor: 6.600

4.  Risks in Induction of Platelet Aggregation and Enhanced Blood Clot Formation in Platelet Lysate Therapy: A Pilot Study.

Authors:  Ying-Hao Wen; Chen-Fang Lee; Yu-Ju Chen; Gwo-Jyh Chang; Kowit-Yu Chong
Journal:  J Clin Med       Date:  2022-07-08       Impact factor: 4.964

5.  Amelioration of Nicotine-Induced Osteoarthritis by Platelet-Derived Biomaterials Through Modulating IGF-1/AKT/IRS-1 Signaling Axis.

Authors:  Wen-Cheng Lo; Navneet Kumar Dubey; Feng-Chou Tsai; Jui-Hua Lu; Bou-Yue Peng; Pao-Chang Chiang; Abhinay Kumar Singh; Chia-Yu Wu; Hsin-Chung Cheng; Win-Ping Deng
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.